Petros Pharmaceuticals(OTC) PTPI

Petros helps men manage health issues like erectile dysfunction and Peyronie’s disease. Its products once included prescription drugs and medical devices for these conditions. Now, Petros is building technology to help move prescription drugs to over-the-counter status.

What’s in the Petros Toolbox?

• Stendra (Discontinued): Prescription pill for erectile dysfunction, previously a main revenue source before discontinuation.
• Vacuum Erection Devices (Discontinued): Non-drug devices for erectile dysfunction, sold under brands like Osbon ErecAid and PosTVac.
• H100 (Development): Patented topical formulation candidate for the treatment of Peyronie’s disease.
• Rx-to-OTC Technology Platform: Software to help pharmaceutical companies switch drugs from prescription to over-the-counter, targeting self-care markets.
• Software as a Medical Device (SaMD): Digital tool for consumers to check if they qualify for over-the-counter drugs, designed to meet U.S. Food and Drug Administration (FDA) rules.

Petros on the Move: Growth and Expansion

• Exited all legacy product sales and divested subsidiaries in June 2025 through assignment for the benefit of creditors.
• Shifted focus in 2025 to developing a proprietary technology platform for prescription-to-over-the-counter drug switches.
• Raised $9.6 million gross ($8.5 million net) in February 2025 public offering to fund new platform development.
• Delisted from Nasdaq in May 2025; now trades on the OTC Markets.

What Makes Petros Stand Out?

Petros has moved from selling men’s health drugs and devices to building a digital platform for drug access. Its new software aims to help companies and consumers navigate the switch from prescription to over-the-counter drugs. The company’s focus is now on technology, not direct product sales.

Five Things You Need to Know

• Revenue was $0 in Q2 2025, down 100% from $1 million in Q2 2024.
• Loss from continuing operations was $3.26 million for six months ended June 2025, up 14% year-over-year.
• Net income was $3.17 million for six months ended June 2025, due to a $6.97 million non-cash gain.
• Cash and cash equivalents were $7.32 million as of June 30, 2025, up from $1.72 million at year-end 2024.
• Petros has no current product sales and faces substantial doubt about its ability to continue as a going concern.

Bottom Line

Petros has exited its legacy men’s health business and now focuses on technology for drug access. The company’s future depends on developing and commercializing its new digital platform.